Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SA55 in COVID-19 patients with hematological disorders
NCT05675943Completed
- Sponsor
- Beijing Boren Hospital
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing SA55 Group with Placebo Group (2 arms). Primary endpoint: Time when the subject has nucleic acid and the antigen test continues to turn negative at 21 days. Started Jan 2023; status: completed.
02
Drugs
SA55
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05675943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05675943.